In vivo effects of a thymosin alpha 1-containing colostral whey product on neutrophils and lymphocytes from lactating cows without and with experimentally induced Staphylococcus aureus mastitis.
Kehrli. M E ME; Nonnecke. B J BJ; Wood. R L RL; Roth. J A JA
Key Findings
- Thymosin‑alpha‑1 slightly raised the proportion of small mononuclear cells in milk and boosted random neutrophil migration by about 73% in healthy cows.
- In cows with induced Staph mastitis, the treatment lowered blood white‑cell counts but kept neutrophil migration steady, while control cows lost this ability.
- Despite these immune tweaks, the treated cows had a 9% higher bacterial load in milk, indicating a worse infection, and there was no impact on milk yield.
Practical Outcomes
- For biohackers, this study suggests that low‑dose thymosin‑alpha‑1 in a whey matrix has limited immune effects and no clear health advantage, and it might even worsen an infection. It provides some safety reassurance (no obvious toxicity) but offers no actionable protocol for humans.
Summary
A study gave cows a whey product containing thymosin‑alpha‑1 and looked at immune changes. It showed a few modest boosts in certain immune cell activities, but it didn’t improve milk production or protect against a Staph infection—in fact, the infected cows shed more bacteria. No bad side effects were seen, but the overall benefit was minimal.
Abstract
Two separate experiments evaluated ID-1 (a commercial bovine whey product containing 5200 pg of thymosin alpha 1/ml) as an immunotherapeutic agent in lactating cows. In the first experiment, cows without mastitis were evaluated for blood leukogram, milk production, total and differential milk cell counts, lymphocyte (Lc) blastogenesis, and neutrophil (PMN) functions (random and directed migration under agarose, chemiluminescence, ingestion of bacteria, iodination, cytochrome C reduction, antibody-independent neutrophil-mediated cytotoxicity, and antibody-dependent cell-mediated cytotoxicity) before and after ID-1 therapy. ID-1 treatment resulted in a significant treatment group by time period interaction for the relative proportion of mononuclear cells (MNC) in milk (P less than 0.009) and for PMN random migration (P less than 0.01). Based on these interactions, ID-1 treatment appeared to slightly increase the proportion of small MNC in milk and to increase random migration from pretreatment levels by 73% more than increases observed in controls. No significant effect of ID-1 treatment on milk production, total milk somatic cell counts, Lc blastogenesis, or other PMN functions was observed. In cows with experimental Staphylococcus aureus intramammary infections, ID-1 treatment resulted in a significant decline in blood leukocyte count (P less than 0.001) and blood PMN count (P less than 0.02), and maintained PMN random migration (P less than 0.01) while controls declined and abrogated a depression in the ability of Lc to respond to mitogens (P less than 0.05) that developed in controls as a result of S. aureus mastitis. Injection of ID-1 into cows had no adverse effect on their overall health or level of milk production, but did cause subtle and potentially favorable changes in several in vitro immune parameters. In spite of these subtle changes which might indicate increased resistance to mastitis, cows actually developed a more severe S. aureus intramammary infection based on a 9% increase in log 10 bacterial shedding in milk.
Study Information
pubmed
1989
10.1016/0165-2427(89)90095-0
11
42